From Imitation to Innovation: A Study of China’s Drug R&D and Relevant National Policies
AbstractResearch & Development (R&D) plays an increasingly important role in China’s pharmaceutical industry. To gain a competitive edge in the global pharmaceutical market, the current national strategy of China forcefully pushes for independent drug innovations. This article investigates the historical, legal, and institutional contexts in which China’s drug R&D has evolved. Based on an analysis of the drug R&D evolution and national policies in China, it predicts the future trend of China’s policies relevant to drug innovations. This paper helps to understand the impact of national policies on drug R&D in China, which can be used to inform decision-making on investments in China’s pharmaceutical market or conducting technology trade and international cooperation with Chinese partners.
BARTLETT, C. A., & Ghosal, S. (2000). Going global: lessons from late movers. Harvard Business Review, 78(2), 132-142.
CHENOWETH, D. (2005). Is more really less in China's new drug approvals? Drug Discovery Today, 10(17), 1140-1142.
DING, J., & M, Z. (2009). The comparative study on supervision and incentive policies of Sino-US during the innovative drug R&D. Chinese Journal of New Drugs, 387-392 (in Chinese).
DU, G. (2005). Current situation and countermesures of IPR in pharmaceutical enterprises. Capital Medicine, 12-14 (in Chinese).
GRANT, R. M. (1996). Toward a Knowledge-Based Theory of the Firm. Strategic Management Journal, 17, 109-122.
LI, Q. (2007). Research on Technology spillover effect by Foreign Direct Investments' on China's pharmaceutical industry. University of International Business & Economics.
LIANG, H., Ding, J., & Xue, Y. (2011). China's drug innovation and policy environment Drug Discovery Today, 16(1-2), 1-3.
LIN, B. (2007). Competition strategy for imitation and generic drugs. China Youth Science and Technology, 21-24(in Chinese).
LIU, C. (2009). Law of Intellectual Property. Beijing: Publishing House of Renmin University of China.
LU, P. (2006). Will Pharmaceutical Industry meet with the low margin age? Dynamics of reform on Drug Prices is still being strengthened. Retrieved November 12, 2009, from http://biz.cn.yahoo.com/06ll24/36/jzt4.html
MAO, J. (2006). Industry agglomeration and human capital accumulation: the cases of Yangtze Delta and Pearl Delta Journal of Beijing Nomal University, 103-110 (in Chinese).
PAN, W., & Chen, L. (2009). Radix Pseudostellariae of Tuorong County being developed as drugs for pediatric usage. Retrieved January 21, 2010, from http://www.zgycsc.com/readinfo-htm-ifid-31902.html
REN, Y. (2009). The best time for drug R&D is coming. Capital Medicine, 16(13), 22-24 (in Chinese).
SUN, Q., Santoro, M. A., Meng, Q., Liu, C., & Eggleston, K. (2008). Pharmaceutical policy in China. Health Affairs, 27(4), 1042-1050.
WANG, L. (2009). SFDA new drug applications decreased quantity while increased quality Retrieved November 12, 2009, from http://info.pharmacy.hc360. com/2009/09/09l0l489948.shtml
WANG, L., & Kang, C. (2005). Research on strategic alliance in pharmaceutical enterprises. Science and Technology Management Research, 111-113 (in Chinese).
YANG, L., Li, Y., & Xu, Y. (2007). Incentive Policies on innovative drug R&D in U.S. Chinese Journal of New Drugs, 985-988 (in Chinese).
YIN, R. K. (2003). Case Study Research Design and Methods (3 ed. Vol. 5). Thousand Oaks: Sage Publications.
ZHANG, X. T., Ping, Q. N., & Hu, B. (2008). A view on correlative factors for the drug innovation system in the US with enlightenments to China. Chin J New Drugs Clin Rem., 27(10), 795-800 (in Chinese).
ZHANG, X. T., Q.N., P., & L.H, A. (2009). The development of the pharmaceutical industry in India and its influencing factors. China Pharmaceutical, 495-498 (in Chinese).
ZHAO, J., Zhang, X. D., Xu, L., & Mao, W. J. (2009). Features of the Revision of Provisions for Drug Registration and Its Effect on Drug R&D. Pharmaceutical Journal of Chinese People's Liberation Army, 280-282 (in Chinese).
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).